Kurs
-1,15%
Likviditet
1,88 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-27 | 08:00 | Bokslutskommuniké 2025 |
2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-22 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-06 | N/A | Årsstämma |
2025-05-06 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-27 | 08:00 | Bokslutskommuniké 2024 |
2024-11-05 | - | Kvartalsrapport 2024-Q3 |
2024-08-22 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2024-05-07 | - | Årsstämma |
2024-05-03 | - | Kvartalsrapport 2024-Q1 |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-11-02 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2023-05-11 | - | Årsstämma |
2023-05-04 | - | Kvartalsrapport 2023-Q1 |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2022-05-11 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-05 | - | Kvartalsrapport 2021-Q1 |
2021-03-05 | - | Extra Bolagsstämma 2021 |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-11-06 | - | Kvartalsrapport 2020-Q3 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-05-22 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2020-05-20 | - | Årsstämma |
2020-05-05 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Kvartalsrapport 2019-Q3 |
2019-08-23 | - | Kvartalsrapport 2019-Q2 |
2019-05-16 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2019-05-15 | - | Årsstämma |
2019-05-15 | - | Kvartalsrapport 2019-Q1 |
2019-02-22 | - | Bokslutskommuniké 2018 |
2019-01-07 | - | Extra Bolagsstämma 2018 |
2018-10-19 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-06-13 | - | Årsstämma |
2018-05-09 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2018-05-08 | - | Kvartalsrapport 2018-Q1 |
2018-02-21 | - | Bokslutskommuniké 2017 |
2017-10-19 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-05-11 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2017-05-10 | - | Årsstämma |
2017-05-10 | - | Kvartalsrapport 2017-Q1 |
2017-03-27 | - | Extra Bolagsstämma 2017 |
2017-02-24 | - | Bokslutskommuniké 2016 |
2016-10-13 | - | Kvartalsrapport 2016-Q3 |
2016-07-08 | - | Kvartalsrapport 2016-Q2 |
2016-04-27 | - | Årsstämma |
2016-04-15 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2016-02-25 | - | Bokslutskommuniké 2015 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Stockholm, February 10, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference.
- Presentation Date and Time: Wednesday, February 12, 2025, at 8:00 AM ET/2:00 PM CET
- Presenter: Ahmed Mousa, CEO
- Webcast: https://wsw.com/webcast/oppenheimer39/vico/2791144
Interested parties may also access the webcast replay on Vicore’s website for 90 days following the conclusion of the event.
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com